Skip to main content

Table 2 Association between the levels of Lp(a) and functional outcomes at 3 months and 1 year

From: Elevated lipoprotein(a) and lipoprotein-associated phospholipase A2 are associated with unfavorable functional outcomes in patients with ischemic stroke

 

Event rate

OR (95% confidence interval)

Unadjusted

Adjusted

mRS ≥ 3 at 3 months

 Lp(a)(Q1)

11.66

Reference

Reference

 Lp(a)(Q2)

14.06

1.24 (1.05–1.47)

1.20 (0.99–1.45)

 Lp(a)(Q3)

14.87

1.32 (1.12–1.56)

1.24 (1.03–1.50)

 Lp(a)(Q4)

17.22

1.58 (1.34–1.86)

1.33 (1.11–1.61)

mRS ≥ 3 at 1 year

 Lp(a)(Q1)

11.52

Reference

Reference

 Lp(a)(Q2)

13.36

1.19 (1.00–1.41)

1.12 (0.92–1.35)

 Lp(a)(Q3)

14.01

1.25 (1.06–1.49)

1.18 (0.97–1.42)

 Lp(a)(Q4)

15.95

1.46 (1.23–1.72)

1.25 (1.04–1.51)

  1. Adjust for age, sex, BMI, Diabetes mellitus, LDL-C, HDL-C, TG, Lp-PLA2, TOAST subtypeand NIHSS score at admission
  2. BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; Lp-PLA2: lipoprotein-associated phospholipase A2; NIHSS: National Institutes of Health Stroke Scale